TABLE 2

Analyses strategy, according to country groups

GroupCountryGNI per capita $CF populationAge composition at base yearMethod used for estimating age composition by year 2025
ABelgium, Czech Republic Denmark, France, UK, the Netherlands24 000–41 000ObservedObservedForecast, flow method in each country
BGermany, Hungary, Ireland, Israel, Latvia, Moldova, Serbia, Sweden, Slovenia, Slovakia3 000–39 000ObservedObservedForecast, flow method using the weighted mean of flows calculated for countries of group A
CAustria, Switzerland, Cyprus, Spain, Finland, Greece, Italy, Luxembourg, Malta, Portugal23 000–53 000Calculated using general population data and CF prevalenceEstimated assuming mean proportion of adults observed in countries of group A: 48.8% of adultsProjection, on the assumption of the weighted mean growth rates of group A countries: increase by 20% in children and by 78% in adults
DEstonia, Lithuania, Poland, Russian Federation18 000–20 000Calculated using general population data and CF prevalenceEstimated assuming 25% of adultsProjection, scenario 1: increase by 20% in children and by 78% in adults; scenario 2: increase by 40% in children and by 40% in adults
Bulgaria, Belarus, Romania, Ukraine7 000–16 000Estimated assuming 15% of adults
  • Country groups were defined as follows, group A: contributing data to the ECFS Patient Registry, coverage ≥85% of the cystic fibrosis (CF) population, longitudinal data linked at the patient level in the ECFS Patient Registry for at least 4 years. Group B: contributing data to the ECFS Patient Registry, coverage ≥85% of the CF population, longitudinal data for <4 years or no longitudinal data. Group C: not contributing data to the ECFS Patient Registry or <85% coverage of the CF population and gross national income (GNI) per capita ≥$23 000. Group D: not contributing data to the ECFS Patient Registry or coverage <85% of the CF population and GNI per capita <$23 000. The GNI per capita was based on purchasing power parity in current international dollars ($).